

FOR IMMEDIATE RELEASE

Chimeracom Receives Patent for Heretofore Unknown Family of Analgesic Drugs

NEW YORK. April 19, 2005. Chimeracom L.L.C. announced today that the US Patent and Trademark Office issued the patent for the invention of Chimeric Hybrid Analgesics. An invention of Chimeracom's Chief Science Officer Dr. Richard M. Kream, the patent covers composition of matter for, and methods of treating pain using, novel conjugate molecules (also called chimeric hybrid molecules).

This new family of pharmaceuticals, the Elpis™ drugs, consists of molecules that conjugate alkaloids (such as morphine) and non-alkaloids. Drugs in the Elpis™ family produce opioid analgesia with little or no development of opioid tolerance or formation of opioid dependence and are expected to have lower potential for misuse and abuse than other opioid analgesics. The Elpis™ drugs are in preclinical testing.

The new US Patent is no. 6,881,829, entitled Chimeric Hybrid Analgesics.

* * * * *

ABOUT CHIMERACOM: Chimeracom is a privately-held company engaged in the research and development of novel analgesic drugs, which will alleviate pain without the adverse side effects of current analgesics, as well as compounds for treating drug abuse. URL: <http://www.chimeracom.net>

Elpis™ is a trade mark of Chimeracom, L.L.C.

DISCLOSURE NOTICE: The information contained in this release is as of April 19, 2005. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward-looking information about Elpis™ drugs that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the completion of preclinical testing, the obtaining of investigational new drug approval and conduct and completion of clinical testing, the obtaining of new drug application approval, whether the Elpis™ drugs will be classified as controlled substances and if so into what controlled substance category, and the speed with which a product launch may be achieved, including the potential for difficulties or delays in manufacturing and marketing.